Fig 1.
Schematic representation of the effects of Ziziphus jujuba seed powder and seed oil on CCl4-induced liver fibrosis.
Table 1.
Experimental design of the in vivo study.
Table 2.
Antioxidant activity of Z. jujuba seed powder and oil.
Table 3.
Compounds identified in the methanolic extract of Ziziphus jujuba seed powder by gas chromatography.
Fig 2.
GC-MS chromatogram of the methanolic extract of Ziziphus jujuba seed powder with bioactive compounds.
Table 4.
Compounds identified in the hexane extract of Z. jujuba seed oil using gas chromatography.
Fig 3.
GC-MS chromatogram of the hexane extract of Z. jujuba seed oil with bioactive compounds.
Fig 4.
Effect of Z. jujuba seed powder and seed oil supplementation on feed intake (g/day) in the different treatment groups.
Fig 5.
Effect of Z. jujuba seed powder and seed oil supplementation on water intake (mL/day) in the different treatment groups.
Table 5.
Effect of Z. jujuba seed powder and seed oil on liver function biomarkers.
Fig 6.
Effect of Z. jujuba seed powder and seed oil on liver function biomarkers: (a) bilirubin, (b) ALT, AST, and ALP in different treatment groups.
Table 6.
Effect of Z. jujuba seed powder and seed oil on liver oxidative stress and fibrosis biomarkers.
Fig 7.
Effect of Z. jujuba seed powder and seed oil on oxidative stress biomarkers: (a) hydroxyproline, (b) MDA, SOD, NOx, Catalase in different treatment groups.
Table 7.
Effect of Z. jujuba seed powder and seed oil on lipid profiles and glucose levels.
Table 8.
Effect of Z. jujuba seed powder and seed oil on inflammation markers.
Fig 8.
Effect of Ziziphus jujuba seed powder and seed oil on serum protein profile (total protein, Albumin, Globulin, A/G ratio) in different treatment groups.
Fig 9.
Effects of Ziziphus jujuba seed powder and seed oil on hematological parameters (RBC, Hb, HCT, MCV, MCH, and MCHC) in different treatment groups.
Fig 10.
Effect of Z. jujuba seed powder and seed oil on (a) leukocyte profile (WBC), (b) lymphocytes, (c) neutrophils, and (d) white blood cell differential counts (monocytes, eosinophils, and basophils) in different treatment groups.